A practical reference on LC-MS/MS: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-11-28 and is reviewed periodically as new material appears.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule ligand; not a hormone or peptide |
| Molecular formula | C20H24ClN3O4S | Reported for the free base |
| CAS Registry Number | 1379686-30-2 | Unique chemical identifier |
| Common synonyms | SR9009; stenabolic | Stenabolic is informal and not an official name |
| Reported targets | REV-ERBα and REV-ERBβ | Nuclear receptors linked to circadian and metabolic regulation |
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
== External links == Idaho U. DNA proofreading and repair "DNA polymerase ε and δ proofreading suppress discrete mutator and cancer phenotypes in mice" Tseng, Shun-Fu; Gabriel, Abram; Teng, Shu-Chun (2008). "Proofreading Activity of DNA Polymerase Pol2 Mediates 3′-End Processing during Nonhomologous End Joining in Yeast". PLOS Genetics. 4 (4) e1000060. doi:10.1371/journal.pgen.1000060. PMC 2312331. PMID 18437220.
On September 12–17, 2013, at the 2013 IBC Conference in Amsterdam, Nagra introduced an Ultra HD User Interface called Project Ultra based on HTML5, which works with OpenTV 5. On October 4, 2013, DigitalEurope announced the requirements for their UHD logo in Europe. The DigitalEurope UHD logo requires that the display support a resolution of at least 3840 × 2160, a 16∶9 aspect ratio, the Rec. 709 (HDTV) color space, 8 bpc color depth, a frame rate of 24, 25, 30, 50, or 60 fps, and at least 2-channel audio. On October 29, 2013, Elemental Technologies announced support for real-time 4K Ultra HD HEVC video processing. Elemental provided live video streaming of the 2013 Osaka Marathon on October 27, 2013, in a workflow designed by K-Opticom, a telecommunications operator in Japan. Live coverage of the race in 4K Ultra HD was available to viewers at the International Exhibition Center in Osaka. This transmission of 4K Ultra HD HEVC video in real-time was an industry-first. On November 28, 2013, Organizing Committee of the XXII Olympic Winter Games and XI Paralympic Winter Games 2014 in Sochi chief Dmitri Chernyshenko stated that the 2014 Olympic Winter Games would be shot in 8K Super Hi-Vision. On December 25, 2013, YouTube added a "2160p 4K" option to its videoplayer. Previously, a visitor had to select the "original" setting in the video quality menu to watch a video in 4K resolution. With the new setting, YouTube users can much more easily identify and play 4K videos.
Chemical inhibiting BMP signals in chicken embryo caused a disruption of MD invagination and blocked the epithelial thickening of the MD-forming region, indicating that the BMP signals play a role in early MD development. Moreover, BMP signaling is involved in the formation of foregut and hindgut, intestinal villus patterning, and endocardial differentiation. Villi contribute to increase the effective absorption of nutrients by extending the surface area in small intestine. Gain or lose function of BMP signaling altered the patterning of clusters and emergence of villi in mouse intestinal model. BMP signal derived from myocardium is also involved in endocardial differentiation during heart development. Inhibited BMP signal in zebrafish embryonic model caused strong reduction of endocardial differentiation, but only had little effect in myocardial development. In addition, Notch-Wnt-Bmp crosstalk is required for radial patterning during mouse cochlea development via antagonizing manner. Mutations in BMPs and their inhibitors are associated with a number of human disorders which affect the skeleton. Several BMPs are also named 'cartilage-derived morphogenetic proteins' (CDMPs), while others are referred to as 'growth differentiation factors' (GDFs). BMPs are also involved in adipogenesis and functional regulation of adipose tissue. BMP4 favors white adipogenesis, whereas BMP7 activates brown fat functionality; BMP inhibitors are also involved in this regulation
== Chromatography == Along with its medical applications, hydroxyapatite is also used in downstream applications under mixed-mode chromatography in polishing step. The ions present on the surface of hydroxyapatite make it an ideal candidate with unique selectivity, separation and purification of biomolecule mixtures. In mixed-mode chromatography, hydroxyapatite is used as the stationary phase in chromatography columns. The combined presence of calcium ions (C- sites) and phosphate sites (P-sites) provide metal affinity and ion exchange properties respectively. The C-sites on the surface of the resin undergo metal affinity interactions with phosphate or carboxyl groups present on the biomolecules. Concurrently, these positively charged C-sites tend to repel positively charged functional groups (e.g., amino groups) on biomolecules. P-sites undergo cationic exchange with positively charged functional groups on biomolecules. They exhibit electrostatic repulsion with negatively charged functional groups on biomolecules. For the elution of molecules buffer with high concentration of phosphate and sodium chloride is used. The nature of different charged ions on the surface of hydroxyapatite provides the framework for unique selectivity and binding of biomolecules, facilitating robust separation of biomolecules. Hydroxyapatite is available in different forms and in different sizes for the purpose of protein purification. The advantages of hydroxyapatite media are its high product stability and uniformity in various lots during its production.
Sources: en.wikipedia.org
NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 2, mitochondrial is an enzyme that in humans is encoded by the NDUFB2 gene. NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 2, 8kDa is an accessory subunit of the NADH dehydrogenase (ubiquinone) complex, located in the mitochondrial inner membrane. It is also known as Complex I and is the largest of the five complexes of the electron transport chain.
=== Leadership === Roger D. Cone began his tenure as the Mary Sue Coleman Director of the University of Michigan Life Sciences Institute in September 2016. A leading researcher in brain regulation of body weight, Cone also serves as vice provost and director of U-M's biosciences initiative. The managing director is Anna Schork. The institute's first director was Jack E. Dixon. In 2002, Mary Sue Coleman, U-M's president, appointed cell biologist and expert on insulin signaling Alan R. Saltiel as director. Saltiel served as the director until 2015, followed by interim director Stephen Weiss, who led the institute from 2015 to 2016.
The western brown snake (Pseudonaja nuchalis) is a highly venomous species of brown snake common throughout Western Australia. Its venom contains powerful neurotoxins, nephrotoxins and a procoagulant, although humans are not usually affected by the neurotoxins. The bite is usually painless and difficult to see due to their small fangs. Human symptoms of a Western Brown snake bite are headache, nausea/vomiting, abdominal pain, severe coagulopathy and sometimes, kidney damage. The LD50 in mice is 0.47 mg/kg and the average venom yield per bite is 18 mg (dry weight of milked venom) according to Meier and White (1995). The western brown snake can cause rapid death in humans by cardiac arrest, kidney failure, or cerebral hemorrhage. The envenomation rate is 20–40% and the untreated mortality rate is 10–20%.
Sources: en.wikipedia.org
On 22 February, however, a Save the Children representative stated, "Even if the war were to end tomorrow, education can not just resume. More than half of Gaza's schools have either been destroyed or are too damaged to even function". In August 2024, UNRWA launched a "back to learning programme" in Khan Younis. In August 2024, the Education Cluster, Save the Children, and UNICEF stated that students and children in Gaza had lost a year of education and warned that the "majority of them may never return to school again". Some students enrolled in online classes or learned in tent classrooms. As of January 2025, children in Gaza had been without formal schooling for over a year. While some informal classes reportedly take place in displacement camps, parents say their children are falling behind academically, forgetting basic literacy skills, or losing crucial years of education altogether.
The endoneurium (also called endoneurial channel, endoneurial sheath, endoneurial tube, or Henle's sheath) is a layer of delicate connective tissue around the myelin sheath of each myelinated nerve fiber in the peripheral nervous system. Its component cells are called endoneurial cells. The endoneuria with their enclosed nerve fibers are bundled into groups called nerve fascicles, each fascicle within its own protective sheath called a perineurium. If sufficiently large, nerves containing multiple fascicles, each with its blood supply and fatty tissue, may be bundled within yet another sheath, the epineurium. The endoneurium contains a liquid known as endoneurial fluid, which contains little protein. In the peripheral nervous system the endoneurial fluid is notionally equivalent to cerebrospinal fluid in the central nervous system. Peripheral nerve injuries commonly release increased amounts of endoneurial fluid into surrounding tissues; these can be detected by magnetic resonance neurography, thereby assisting in locating injuries to peripheral nerves. The endoneurium runs longitudinally along the nerve fiber, but with discontinuities where septa pass inward from the innermost layer of the perineurium. It contains fine bundles of fibrous connective tissue, primarily collagen, embedded in a matrix of ground substance. This structure serves to support capillary blood vessels, arranged so as to form a network of elongated meshes.
== Biological activity == Concanavalin A interacts with diverse receptors containing mannose carbohydrates, notably rhodopsin, blood group markers, insulin receptors, the immunoglobulins and the carcino-embryonary antigen (CEA). It also interacts with lipoproteins. ConA strongly agglutinates erythrocytes irrespective of blood-group, and various cancerous cells. It was demonstrated that transformed cells and trypsin-treated normal cells do not agglutinate at 4 °C, thereby suggesting that there is a temperature-sensitive step involved in ConA-mediated agglutination. ConA-mediated agglutination of other cell types has been reported, including muscle cells, B-lymphocytes (through surface immunoglobulins), fibroblasts, rat thymocytes, human fetal (but not adult) intestinal epithelial cells, and adipocytes. ConA is a lymphocyte mitogen. Similar to phytohemagglutinin (PHA), it is a selective T cell mitogen relative to its effects on B cells. PHA and ConA bind and cross-link components of the T cell receptor, and their ability to activate T cells is dependent on expression of the T cell receptor. ConA interacts with the surface mannose residues of many microbes, including the bacteria E. coli, and Bacillus subtilis and the protist Dictyostelium discoideum. It has also been shown as a stimulator of several matrix metalloproteinases (MMPs). ConA has proven useful in applications requiring solid-phase immobilization of glycoenzymes, especially those that have proved difficult to immobilize by traditional covalent coupling.
Sources: en.wikipedia.org
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.
No. It has no approved medical indication, and human safety and efficacy data are limited. It appears in research chemical markets and is banned by some sports authorities.
Natural ligands include heme and certain metabolites; SR9009 is a synthetic small molecule with higher potency and selectivity in some assays. Its effects depend on cell type and timing. It is not a naturally occurring compound.
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.